Aberration of the p53 gene is thought to be the most frequent genetic alteration in human
cancers. Tp53 protein may be inactivated by the binding of the MDM2 protein. MDM2, the …

Abstract Background and Aims: Nutlin‐3, a selective small‐molecule inhibitor of the p53‐
MDM2 interaction, has been shown to have antitumor activities in various tumors with wild …

The tumor suppressor p53 is tightly controlled at low levels in cells by constant ubiquitination
and proteasomal degradation. In response to stresses, ubiquitination of p53 is inhibited …

The ability of cancer cells to survive and grow under hypoxic conditions has been known for
decades, but the mechanisms remain poorly understood. Under certain conditions, cancer …

Notwithstanding the numerous drugs available for liver cancer, emerging evidence suggests
that chemotherapeutic resistance is a significant issue. HGF and its receptor MET play …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide
and is considered to be the outcome of chronic liver inflammation. Currently, the main …

Liver cancers consist primarily of hepatocellular carcinoma (HCC) and intrahepatic
cholangiocarcinoma (ICC). Immune checkpoint inhibitors have emerged as promising …

Posttranslational modifications represent a key step in modulating programmed death-1 (PD-
1) functions, but the underlying mechanisms remain incompletely defined. Here, we report …

RNA modification of m6A/m5C/m1A contributes to the occurrence and development of
cancer. Consequently, this study aimed to investigate the functions of m6A/m5C/m1A …

Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies and lacks
targeted therapies. Here, we reported a novel potential therapeutic target hematological and …